Search | Clinical Trials Finder

Conditions: Recurrent Urinary Tract Infection, Vaginal Atrophy, Postmenopausal Disorder
Interventions: Vaginal Cream with Applicator; Drug
Lead sponsor: Jefferson Drapkin; Other
Eligibility: 60 Years to 90 Years · Female only
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Endothelial Dysfunction
Interventions: Atazanavir, Lopinavir/ritonavir, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Erythematotelangiectatic Rosacea
Interventions: CD07805/47, CD07805/47 placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 5
States / cities: Hot Springs, Arkansas • Fort Washington, Pennsylvania • Austin, Texas + 2 more

Conditions: Post-Dural Puncture Headache
Interventions: Lidocaine HCl Gel 2%, placebo gel; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 50 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Klinefelter Syndrome, XXY Syndrome
Interventions: Testosterone gel 1%, Placebo gel; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 8 Years to 18 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Acne
Interventions: Clindamycin and Benzoyl Peroxide Gel (combination), Clindamycin and Benzoyl Peroxide Gel (Reference) (combination), Placebo gel (combination); Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 890 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Breast Carcinoma In Situ, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions: Endoxifen Hydrochloride, Placebo Administration, Questionnaire Administration; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Chicago, Illinois • New York, New York

Conditions: Venous Malformation, Lymphatic Malformation, Venolymphatic Malformation
Interventions: VT30; Drug
Lead sponsor: Venthera, Inc., a BridgeBio company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 12 more

Conditions: Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ, Breast Atypical Lobular Hyperplasia, Breast Carcinoma
Interventions: Tamoxifen, Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day, Placebo, Questionnaire Administration; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Evanston, Illinois • Rochester, Minnesota • Camden, New Jersey

Conditions: Oral Bacteria Levels in the Mouth
Interventions: Total Flavor option 1, Total Flavor option 2, Placebo toothpaste: Crest Cavity Protection toothpaste; Drug
Lead sponsor: Colgate Palmolive; Industry
Eligibility: 22 Years to 58 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Molluscum Contagiosum
Interventions: SB206 12%, Placebo; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 35
States / cities: Mobile, Alabama • Glendale, Arizona • Little Rock, Arkansas + 32 more

Conditions: Actinic Keratosis
Interventions: Diclofenac sodium, Placebo; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 30
States / cities: Mesa, Arizona • Tucson, Arizona • Fremont, California + 23 more

Conditions: Prevention of Nausea Associated With Motion Sickness, Treatment of Nausea Associated With Motion Sickness
Interventions: Scopolamine Transdermal Patch [Transderm Scop], Scopolamine, Placebo Patch, Placebo Gel; Drug
Lead sponsor: Naval Aeromedical Research Unit, Dayton; Federal
Eligibility: 18 Years to 59 Years
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Metabolic Syndrome
Interventions: Zoladex, Testosterone gel, Anastrozole Pill, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years to 75 Years · Male only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Vitamin D Deficiency, Vitamin D Insufficiency
Interventions: Vitamin D, Placebo, Standard of Care; Dietary Supplement · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Prevention
Interventions: Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel, Universal HEC Placebo Gel Formulation; Drug
Lead sponsor: Ian McGowan; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 2
States / cities: Los Angeles, California • Pittsburgh, Pennsylvania

Conditions: Contraception
Interventions: ContraGel, HEC Universal Placebo gel; Device
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Osteo Arthritis Knee
Interventions: Geniculate Artery Embolization, Sham Procedure; Device · Diagnostic Test
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 40 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Woodbridge, Virginia

Conditions: Toothache
Interventions: Placebo gel, benzocaine; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 8
States / cities: Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 5 more

Conditions: Acne Vulgaris
Interventions: Adapalene, Differin®, Placebo; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 20
States / cities: Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 15 more

Conditions: Ocular Blood Flow
Interventions: Experimental, Placebo; Dietary Supplement
Lead sponsor: LycoRed Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Alzheimer's Disease
Interventions: icosapent ethyl (IPE), gel cap placebo; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years to 75 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Acute Burns
Interventions: Magellan®, Placebo Saline Gel and Usual and Customary Standard of Care; Device · Other
Lead sponsor: Arteriocyte, Inc.; Industry
Eligibility: 18 Years to 86 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 3
States / cities: Sacramento, California • Washington D.C., District of Columbia • Salt Lake City, Utah

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: Lovaza, placebo control; Drug
Lead sponsor: Huntington Medical Research Institutes; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Pasadena, California

Search by objective public record fields.

Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo

Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors

Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea

RCT of SPG Blocks for Post-dural Headache

Study of Psychological and Motor Effects of Testosterone in Adolescents With XXY/Klinefelter Syndrome

Comparative Safety and Efficacy of Two Treatments in the Treatment of Acne Vulgaris

Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery

First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

Clinical Investigation to Examine Toothpaste Effect on Oral Bacteria

A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp

Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels

Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome

Vitamin D to Improve Nutrition Prior to Bariatric Surgery and Investigate the Relationship With Negative Outcomes

A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally

A Safety Study Of The Caya® Diaphragm Used With ContraGel®

Geniculate Artery Embolization for Knee Pain Secondary to Osteoarthritis (OA)

Benzocaine Gel Toothache Dose-Response Study

Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris

The Effects of LycoRed Phytonutrient and Vitamin Supplement (a.k.a. LYC-001e) on Ocular Blood Flow

Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid

Using Autologous Platelet Rich Plasma (PRP) Gel to Treat Deep 2nd and 3rd Degree Burns

Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease